Northwell Health and START open early-phase cancer trial facility
Northwell Health and the START Center for Cancer Research have inaugurated a $5.7mearly-phase cancer clinical trial centre in the US.…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Affibody’s ABY-271 breast cancer trial cleared to progress to next phase
Affibody has received a recommendation from its Trial Review Committee (TRC) to proceed to the second part of its Phase…
-
First patient treated in trial of Beacon Therapeutics’ XLRP treatment
Beacon Therapeutics has treated the first patient in its open-label LANDSCAPE trial of the potential gene therapy, laru-zova (laruparetigene zovaparvovec),…
-
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron replacement cell…
-
argenx to discontinue Phase III trials of thyroid eye disease therapy
argenx has announced the discontinuation of the Phase III UplighTED trials of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in…
-
Alphyn secures $25m in Series B for trial of Zabalafin Hydrogel
Alphyn Biologics has completed $25m in a Series B funding round to support the global Phase IIb trial of its…
-
Anova introduces AI patient matching solution for clinical trials
Anova Enterprises has launched the AnovaOS software-as-a-service (SaaS) platform, a new AI-based patient matching solution for clinical trials. The solution…
-
FDA grants clearance to Prilenia and Ferrer’s Phase III ALS therapy trial
The US Food and Drug Administration (FDA) has granted clearance to Prilenia Therapeutics and Ferrer to commence a Phase III…
-
Lindus Health and Quotient Sciences to support sponsors with trial recruitment
Lindus Health and Quotient Sciences have entered a strategic collaboration to support biotech and pharmaceutical sponsors with subject recruitment for…
-
UK MHRA clears Ensoma’s EN-374 trial application for X-CGD
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared Ensoma’s clinical trial authorisation (CTA) application for its in…